Pfizer Inc. PFE
29.23 USD -0.22 (-0.75%)
Nov 12, 2026, 12:00 PM EST
29.06 Day range 29.77
23.62 52-week range 31.44
- YTD
- +17.39%
- 1 year
- +12.99%
News
zacks.com Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity Program PFE gets up to $1.5 billion from Blackstone to fund berobenatide's development through 2028, retaining full control of the obesity program.
barrons.com Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug Blackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer's berobenatide through 2028 in exchange for milestone-based payments.
benzinga.com Blackstone Bankrolls Pfizer’s Weight Loss Drug Trials for Slice of Future Sales Pfizer and Blackstone Life Sciences signed a $1.5 billion deal to fund berobenatide, a monthly GLP-1 obesity drug entering 10 Phase 3 trials in 2026.
benzinga.com Eli Lilly Wins China Approval for First GLP-1 Weight-Loss Pill, Giving It First-Mover Edge In Potential $4.5 Billion Market: Report Eli Lilly wins China approval for its first GLP-1 weight-loss pill, gaining an early edge in the country's $4.5 billion market.
wsj.com Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development The investment is set to cover development costs for berobenatide, an investigational drug being studied for chronic weight management and obesity-related conditions.
reuters.com Pfizer secures up to $1.5 billion from Blackstone for obesity drug development Pfizer secures up to $1.5 billion from Blackstone for obesity drug development
benzinga.com Pfizer And Blackstone Life Sciences Enter Co-Funding Agreement Under Which Blackstone Will Pay Up To $1.5B Of Development Costs For Study Of Monthly GLP-1 Receptor Agonist Peptide Berobenatide Through 2028 Berobenatide is an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide being studied for chronic weight management and obesity-related conditions. In exchange for the…
businesswire.com Pfizer and Blackstone Life Sciences Announce Strategic Funding Agreement for Obesity Program NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Blackstone Life Sciences (“Blackstone”) today announced a strategic co-funding agreement under which funds managed by…
247wallst.com Americans Fill Prescriptions Every Month, and $90,000 Across These 3 Drugmakers Pays $3,650 a Year Every one of these drugmakers is staring down a patent cliff, and that looming drop in sales is exactly why their dividends pay what they do. Which one carries the most risk, and which one rewards…
fool.com 3 Magnificent Dividend Stocks Yielding 4% or More to Buy in November These three blue chip dividend stocks offer higher yields while standing out in terms of dividend coverage and growth.
businesswire.com Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer,…
fool.com Pfizer Hits a New 52-Week High. Here's Why It's Not Too Late to Buy the Stock Pfizer's recently launched and acquired products have been generating impressive growth. The stock is up big this year, but its valuation remains modest based on analyst expectations.
zacks.com Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
fool.com Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028 Pfizer acquired a promising GLP-1 drug last year through its purchase of Metsera. It plans to eventually launch both weekly and monthly versions of the treatment.
benzinga.com Medicus Pharma Unveils Capital Strategy Centered On Novel Cancer Pipeline Medicus Pharma advances its Pfizer-partnered cancer asset and plans a $135 million SkinJect SPAC deal while reducing quarterly operating expenses.
fool.com Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials Eli Lilly is the leader in the GLP-1 weight-loss space, with Novo Nordisk working hard to regain lost market share. Pfizer had to drop its GLP-1 drug candidate, but quickly pivoted by acquiring a new…
fool.com 3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market They are so much more than just dividend stocks.
247wallst.com Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
seekingalpha.com November Buy: 6 IDEAL S&P 500 'Safer' Dividend Dogs Six S&P 500 'safer' high-yield dividend stocks—Regions Financial, Ford, AT&T, Pfizer, Verizon, VICI Properties—currently offer attractive buy signals based on free cash flow yields. Analyst…
seekingalpha.com Diamond Hill Large Cap Fund Q3 2026 Portfolio Update The Fund returned 3.18% compared to a 2.61% return for the Russell 1000 Value Index. Key contributors include Microsoft, Salesforce and Thermo Fisher Scientific. Key detractors include Aon, Carrier…
247wallst.com 5 High-Yield Dividend Stocks That Could Hold Up When the Market Falls Drugs, software, cereal, and electricity keep selling when the economy stalls. Five dividend payers pass a coverage test, but one carries a payout stretched thin and another faces a regulatory…
247wallst.com Buy, Sell, or Hold? Friday’s Top Upgrades and Downgrades: Becton Dickinson, BJ’s Wholesale Club, Cogent Communications, Fervo Energy, JinkoSolar, Molson-Coors, Pfizer, SiTime, Steven Madden, and More After a brutal sell-off erased Wednesday's rally and dragged the Nasdaq back into correction territory, Wall Street analysts are still moving. Some reversed course on Pfizer, Molson Coors, and BJ's,…
defenseworld.net Pfizer (NYSE:PFE) Hits New 12-Month High on Analyst Upgrade Pfizer Inc. (NYSE: PFE - Get Free Report) shares reached a new 52-week high on Thursday after Guggenheim raised their price target on the stock from $31.00 to $33.00. Guggenheim currently has a buy…
fool.com Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027? Amgen produces strong revenue growth and healthy margins by focusing on complex biological therapies and rare diseases. Pfizer maintains a massive global reach and offers a more conservative balance…
benzinga.com Guggenheim Maintains Buy on Pfizer, Raises Price Target to $33 Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and raises the price target from $31 to $33.
247wallst.com Are Your Dividends Safe? 4 Companies Whose Debt Is Competing With the Payout When a heavily indebted company has to refinance at higher rates, every extra dollar of interest comes out of the same cash pool that funds the dividend. Bondholders have a legal claim on that cash.
defenseworld.net Pfizer Inc. $PFE Shares Newly Acquired by Associated Banc Corp Associated Banc Corp bought a new stake in Pfizer Inc. (NYSE: PFE) in the undefined quarter, according to its most recent disclosure with the SEC. The fund bought 100,353 shares of the…
seekingalpha.com Pfizer: The Portfolio Transformation Is Gaining Momentum Pfizer remains a Buy as its robust pipeline and strategic acquisitions drive portfolio adaptation ahead of the LOE cliff. PFE delivered a double-beat Q3, raised 2026 guidance, and posted strong…
benzinga.com Scotiabank Maintains Sector Outperform on Pfizer, Raises Price Target to $35 Scotiabank analyst Louise Chen maintains Pfizer (NYSE:PFE) with a Sector Outperform and raises the price target from $33 to $35.
benzinga.com Citigroup Maintains Neutral on Pfizer, Raises Price Target to $30 Citigroup analyst Geoff Meacham maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $27 to $30.- benzinga.com RBC Capital Maintains Sector Perform on Pfizer, Raises Price Target to $28 RBC Capital analyst Trung Huynh maintains Pfizer (NYSE:PFE) with a Sector Perform and raises the price target from $25 to $28.
benzinga.com Amazon, Pfizer, Eaton And A Financial Stock On CNBC’s ‘Final Trades’ CNBC's Final Trades: Brown picked Amazon, Lebenthal chose BlackRock, Snipe backed Eaton, and Terranova recommended Pfizer.
benzinga.com Nasdaq Jumps Over 200 Points as Chip Stocks Gain: Fear & Greed Index Remains in ‘Extreme Fear’ Zone Markets closed mixed as CNN Fear & Greed stayed at 19 (Extreme Fear); Nasdaq rose 0.83%, Dow fell, Apple dropped and Aehr surged 26%.
benzinga.com Nasdaq Surges 1%; Pfizer Posts Upbeat Q3 Earnings U.S. stocks were mixed as Nasdaq gained 1%; Pfizer beat Q3 estimates and raised 2026 guidance, while oil, gold and European shares fell.
benzinga.com Pfizer Q3 2026 Earnings Call Transcript Pfizer (NYSE:PFE) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Non-COVID Portfolio Steps Up: Pfizer Outpaces Consensus and Hikes Guidance Pfizer beats Q3 revenue and profit forecasts on oncology and non-COVID drug growth, raising its full-year 2026 sales and EPS outlook.
benzinga.com Pfizer Raises FY2026 Adj EPS Guidance from $2.80-$3.00 to $2.95-$3.05 vs $2.96 Est; Raises FY2026 Sales Guidance from $60.500B-$62.500B to $62.000B-$64.000B vs $62.166B Est Pfizer (NYSE:PFE) raises FY2026 Adj EPS guidance from $2.80-$3.00 to $2.95-$3.05 vs $2.96 analyst estimate. Raises FY2026 sales outlook from $60.500 billion-$62.500 billion to $62.000 billion-$64.000…- benzinga.com Pfizer Q3 Adj. EPS $0.87 Beats $0.72 Estimate, Sales $16.583B Beat $15.872B Estimate Pfizer (NYSE:PFE) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $0.72 by 19.18 percent. This is unchanged from the same period last year. The company…
- benzinga.com Pfizer Appoints Cecile Guegan As CFO And EVP, Effective November 1, 2026 Cecile Guegan to lead Pfizer’s financial strategy as Chief Financial Officer with over 25 years of pharmaceutical finance experiencePfizer Inc. (NYSE:PFE) today announced that its Board of Directors…
benzinga.com Top Wall Street Forecasters Revamp Pfizer Expectations Ahead Of Q3 Earnings Pfizer will report Q3 earnings Nov. 3; analysts expect EPS to fall to $0.73 and revenue to $15.88B, while recent ratings remain mixed.
benzinga.com Nasdaq Dips Over 1% as Tech Stocks Fall: Investor Sentiment Weakens, Fear & Greed Index Moves to ‘Extreme Fear’ Zone CNN Fear & Greed fell to 23, signaling Extreme Fear, as tech stocks dragged Nasdaq down 1.07%; Dow rose 214 points amid U.S.-Iran diplomacy hopes.
benzinga.com Pfizer, Apple and 3 Stocks to Watch Heading Into Tuesday Pfizer and Keurig Dr Pepper report earnings; Apple, Palantir and AMD draw attention after results, guidance and trading moves.
benzinga.com Stock Market: Will S&P 500 Open Up or Down Today? Will the S&P 500 open higher? Polymarket odds dip to 45% as Wall Street navigates Election Day, AMD earnings, and a volatile oil market.
benzinga.com AMD, Shopify On Deck Tuesday As AI Spending, Merchant Growth Face Test Advanced Micro Devices headlines Tuesday’s reports, with investors looking for evidence that AI demand can withstand a sharp pullback in the stock. Shopify, Pfizer, Eaton, Marathon Petroleum and…
benzinga.com AMD Could Swing $90.7 Billion After Earnings Seven major companies are set to report earnings Tuesday, and options traders are pricing in significant stock moves. From Pfizer’s modest 4.14% implied move to Shopify’s 13.01% swing, here’s a…
benzinga.com How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings Pfizer expects Q3 EPS of 73¢ and revenue of $15.88B; its 5.64% dividend yield requires ~$106,454 to generate $500 monthly.
benzinga.com Pfizer Cancer Therapy Shows Extended Progression-Free Survival in Multiple Myeloma Patients Pfizer reports positive Phase 3 ELREXFIO data showing reduced disease progression risk in relapsed or refractory multiple myeloma patients.
benzinga.com Pfizer Announces That Topline Results In The Phase 3 MagnetisMM-32 Trial Of ELREXFIO Demonstrated Clinically Meaningful And Statistically Significant Benefit For Patients Whose Disease Progressed After Anti-CD38 Therapy And Lenalidomide, With Median PFS Not Yet Reached Pfizer Inc. (NYSE:PFE) today announced topline results from the Phase 3 MagnetisMM-32 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma…- benzinga.com Reported Saturday, Pfizer Presents Phase 2 25vPnC Infant Data At IDWeek 2026: Robust Responses To All 25 Serotypes, Including Five New, Safety Comparable To PREVNAR 20, No Related Serious Adverse Events Investigational vaccine shows strong immune responses in infants equivalent to PREVNAR 20 on shared serotypes and for five new serotypes, potentially offering the broadest protection against invasive…
benzinga.com Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields Analysts highlight high-yield healthcare stocks Perrigo (7.09%), Pfizer (5.65%) and CVS Health (2.82%), with updated ratings and news.